Premium
Determination of malondialdehyde by capillary electrophoresis, application to human plasma and relation of its levels with prematurity
Author(s) -
Korizis K. N.,
Exarchou A.,
Michalopoulos E.,
Georgakopoulos C. D.,
Kolonitsiou F.,
Mantagos S.,
Gartaganis S. P.,
Karamanos N. K.
Publication year - 2001
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.78
Subject(s) - malondialdehyde , chemistry , lipid peroxidation , thiobarbituric acid , chromatography , capillary electrophoresis , retinopathy of prematurity , oxidative stress , detection limit , human plasma , biochemistry , gestational age , pregnancy , biology , genetics
Malondialdehyde (MDA) is considered as the most important marker for monitoring lipid peroxidation, which is strongly associated with the development of serious diseases in adults and premature neonates. In this paper we report a method for determination of free MDA in human plasma using capillary zone electrophoresis. MDA was separated and determined as conjugate with tetrabutylammonium hydrogen sulphate (TBAS). Analysis was performed using 20 m M borare, pH = 9.3, as operating buffer and detection of the MDA–TBAS adduct at 267 nm. The method has a linear range up to 80 µ M with a detection limit of 0.2 µ M . The method was applied to the analysis of MDA in plasma of healthy adults, normal‐gestation infants and of preterm neonates. Plasma proteins were successfully removed following centrifugation through a centricon‐3 membrane. Results showed that the method can be easily and accurate applied for the determination of MDA in human plasma and that the level of MDA in pretern neonates is significantly higher ( p ≤ 0.001) as compared to the two other cases. This suggests that MDA analysis may be useful to monitor the development and process of diseases related to lipid peroxidation, oxidative stress and prematurity. Copyright © 2001 John Wiley & Sons, Ltd. Abbreviations used: BHT 2,6‐ditetrabutyl‐4‐methylphenolMDA molandialdehydeROP retinopathy of prematurityTBA thiobarbituric acidTBAS tetrabutylammonium hydrogen sulphate.